Photo of Tom Powles taken from bartscancer.london
May 23, 2024, 13:04
Tom Powles on the NADINA trial
Tom Powles, Director of Barts Cancer Center, shared a post on X:
“The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung.”
Read further.
Source: Tom Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46